PARP1 and neoplasm: After receiving treatment with PARP inhibitors, tumor cells release double-stranded DNA fragments, thereby activating the stimulator of interferon genes (STING) signaling pathway in dendritic cells within the tumor, triggering type I interferon (IFN) response to recruit CD8+ T cells [25].